TABLE 1.
Characteristic | N=36,223 |
---|---|
Sex | |
Boys/Men | 16,906 (46.7) |
Girls/Women | 19,317 (53.3) |
Age as of 12/31/2012 (years) | |
9.5–<11 | 2,912 (8.0) |
≥11–<13 | 3,648 (10.1) |
≥13–<16 | 5,434 (15.0) |
≥16–<22 | 11,316 (31.2) |
≥22–<27 | 10,635 (29.4) |
27 | 2,278 (6.3) |
Race | |
White | 28,268 (78.0) |
Asian | 1,706 (4.7) |
Black or African American | 2,388 (6.6) |
Other or unknown | 3,861 (10.7) |
Insurance statusa | |
No/unknown | 6,437 (17.8) |
Commercial | 22,921 (63.3) |
Government | 4,589 (12.7) |
Other | 2,276 (6.3) |
Completion of 2 doses of the HPV vaccineb | 9,283 (25.6) |
Duration between first and second dose (months), median (IQR)c | 2.7 (2.1, 5.4) |
Completion of 3 doses of the HPV vaccineb | 6,989 (19.3) |
Duration between first and third dose (months), median (IQR)c | 2.5 (2.1, 4.5) |
Abbreviations: IQR, interquartile range
Results presented as N (%) unless otherwise noted.
Insurance status closest to August 2, 2006.
Receipt of doses with appropriate timing (The second dose must have been administered at least 4 weeks (24 days) after the first dose. The third dose must have been administered at least 12 weeks (80 days) after the second dose, and at least 24 weeks (164 days) after the first dose. A 4-day grace period was permitted at each dose.)